<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03962803</url>
  </required_header>
  <id_info>
    <org_study_id>2018ZX10721202001002001</org_study_id>
    <nct_id>NCT03962803</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Persistence of Hepatitis B Vaccination in HIV-Infected Patients</brief_title>
  <official_title>A Prospective Study on the Immunogenicity and Persistence of Hepatitis B Vaccine in HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanxi Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present, HIV-Infected Patients of Hepatitis B Vaccination in are vaccinated with hepatitis
      B vaccine according to the standard three-dose schedule immunization program, and the effect
      of preventing HBV infection is not ideal.

      This is a randomized, controlled trial. The study will evaluate the immunogenicity and
      persistence of 20 µg and 60 µg recombinant hepatitis B vaccine with three or four injections
      at months 0, 1, and 6 or 0, 1,2, and 6 in HIV-Infected Patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants are randomized in a ratio of 1:1:1 into 20 µg recombinant hepatitis B vaccine
      group at months 0, 1, and 6 or 20µg recombinant hepatitis B vaccine group at months 0, 1, 2,
      and 6 or 60µg recombinant hepatitis B vaccine group at months 0, 1, 2, and 6. HBsAg and
      anti-HBs will be tested during the study period. Adverse reactions will be recorded after
      vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 5, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-HBs Seroconversion Rate at Month 7</measure>
    <time_frame>Month 7</time_frame>
    <description>Anti-HBs Seroconversion Rate at month 7 as measured by CMIA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs concentration at month 7</measure>
    <time_frame>Month 7</time_frame>
    <description>Anti-HBs concentration at month 7 as measured by CMIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events After Vaccination</measure>
    <time_frame>Within 7 days after the vaccination</time_frame>
    <description>Occurrence of adverse reactions within 7 days after vaccination with the hepatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs Seroconversion Rate at month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Anti-HBs Seroconversion Rate at month 12 as measured by CMIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs concentration at month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Anti-HBs concentration at month 12 as measured by CMIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs Seroconversion Rate at month 18</measure>
    <time_frame>Month 18</time_frame>
    <description>Anti-HBs Seroconversion Rate at month 18 as measured by CMIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs concentration at month 18</measure>
    <time_frame>Month 18</time_frame>
    <description>Anti-HBs concentration at month 18 as measured by CMIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs Seroconversion Rate at month 30</measure>
    <time_frame>Month 30</time_frame>
    <description>Anti-HBs Seroconversion Rate at month 30 as measured by CMIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs concentration at month 30</measure>
    <time_frame>Month 30</time_frame>
    <description>Anti-HBs concentration at month 30 as measured by CMIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs Seroconversion Rate at month 42</measure>
    <time_frame>Month 42</time_frame>
    <description>Anti-HBs Seroconversion Rate at month 42 as measured by CMIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs concentration at month 42</measure>
    <time_frame>Month 42</time_frame>
    <description>Anti-HBs concentration at month 42 as measured by CMIA</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hepatitis B Vaccine</condition>
  <arm_group>
    <arm_group_label>20 µg at months 0, 1, and 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 µg at months 0, 1, 2,and 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60 µg at months 0, 1, 2,and 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>20 µg recombinant hepatitis B vaccine at months 0, 1, and 6</intervention_name>
    <description>three-dose, 20 µg per dose</description>
    <arm_group_label>20 µg at months 0, 1, and 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6</intervention_name>
    <description>four-dose, 20 µg per dose</description>
    <arm_group_label>20 µg at months 0, 1, 2,and 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6</intervention_name>
    <description>four-dose, 60 µg per dose</description>
    <arm_group_label>60 µg at months 0, 1, 2,and 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Serologically negative for hepatitis B surface antigen (HBsAg), hepatitis B surface
             antibody (anti-HBs) and hepatitis B core antibody (anti-HBc) at enrollment

          -  Sign informed consent, willing to participate in this study

        Exclusion Criteria:

          -  Being pregnant

          -  Intolerance or allergy to any component of the vaccine

          -  Any vaccination during the month preceding enrollment

          -  CD4 cell count ≤ 200 cells/µL

          -  Patients with severe acute or chronic diseases (such as liver disease, blood disease,
             cancer), acute onset of chronic diseases and fever

          -  The use of immunosuppressive agents in patients with nearly three months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suping Wang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanxi Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suping Wang, PhD</last_name>
    <phone>#86-351-4135103</phone>
    <email>spwang88@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yongliang Feng, PhD</last_name>
    <phone>#86-351-4135362</phone>
    <email>fengyongliang048@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanxi Center for Disease Control and Prevention</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2019</study_first_posted>
  <last_update_submitted>May 23, 2019</last_update_submitted>
  <last_update_submitted_qc>May 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanxi Medical University</investigator_affiliation>
    <investigator_full_name>Suping Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hepatitis B Vaccine</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>HIV-Infected Patients</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Long-term Immune Response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

